MUC1 and breast cancer: Additional HER2-derived peptide cancer vaccines have demonstrated beneficial impacts on BC antitumor immunity and clinical outcome, such as GP2 and AE37 (92), folate receptor α peptide vaccine (93) (NCT03012100), sialyl-Tn (sTn) conjugated to keyhole limpet hemocyanin (KLH) (94), and oxidized mannan-MUC-1 vaccine (95).